Meet us at MEDICA 2022 Meet us at MEDICA 2022 and Discover our Microbiology Genotyping SolutionsABL will be attending the next MEDICA forum in Düsseldorf from 14 – 17 November 2022 (Luxembourg Ministry of Economy – Hall 3 / A74). Please come by our booth. We will introduce you our 360° expertise in molecular diagnostics and genotyping by […]
Meet us at MEDICA 2022 Read More »
ABL Diagnostics sponsored the NTDD Symposium in Utrecht (NL) ABL Diagnostics sponsored the NTDD Symposium in Utrecht and presented the DeepChek® kit for Tuberculosis Genotyping & Drug Resistance through NGS sequencing 🧬. Our Sales representatives Vito Grasso and Joffrey BIGNOUNGA had the opportunity to meet the very kind Dutch TB community.
ABL Diagnostics sponsored the NTDD Symposium in Utrecht Read More »
Set up of New Generation Sequencing (NGS) for the detection of Ganciclovir Resistance in the Molecular Biology Laboratory of the Hospital de Clínicas. We would like to thank our local representative in Uruguay Biko which is our local representative in Uruguay and Molecular Biology Laboratory of the Hospital de Clínicas for highlighting our CMV genotyping
ABL DIAGNOSTICS, key player in the diagnosis of infectious diseases by genotyping, presents its development plan to the financial community ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community. Formed from the end-August 2022 merger of ABL France into the listed entity without activity ETABLISSEMENTS FAUVET-GIREL
ABL Diagnostics at the Federation of Infection Societies congress Discover the scientific publications from our Innovation team and get more information about new products & services including: Publication #1 (Poster n°98) Whole Genome Sequencing of Human BK Polyomavirus Using Next-Generation Sequencing View Descamps Veronique1, Morel Virginie1, Olivia Ardizzoni, Amira Doudou, Chalom Sayada, Sofiane Mohamed, and Brochot
ABL Diagnostics at the Federation of Infection Societies congress Read More »
WHO algorithm v2021-06 for Tuberculosis resistance now available! We are pleased to announce the immediate availability of the WHO Catalog of Mutations (version 2021-06) in BacterioChek-TB, intended to be used for Mycobacterium tuberculosis drug resistance assessement. ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574
WHO algorithm v2021-06 for Tuberculosis resistance now available! Read More »
ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™” ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope
ABL received CE-IVD Mark for its “UltraGene™ Assay SARS-CoV-2 PrimeChek™” Read More »
DeepChek-HIV Whole genome Sequencing assay now CE IVD marked ! ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat E1 75020, PARIS FRANCE Phone : +33 145 061 574 Email : contact@abldiagnostics.com Email 2 : fauvet-girel@ablsa.com Envelope
DeepChek-HIV Whole genome Sequencing assay now CE IVD marked ! Read More »
This week we are proud to have two new Distribution Partners on our side : – ELTA 90 Medical Genetics in Georgia– Infotec in Paraguay Both agreements will cover all ABL’s Diagnostics line of products, including the DeepChek® Assays and Software. See all the current Distributors ABL DIAGNOSTICS S.A. 42, rue Olivier Métra – Bat
New Distribution Partners in Georgia & Paraguay ! Read More »
Signature d’un traité de fusion Le Conseil d’administration de la société ABL Diagnostics (la « Société »), réuni le 13 juin 2022, a approuvé le projet de fusion-absorption aux termes duquel il est prévu que la Société absorbe la société Advanced Biological Laboratories Fedialis (« ABL France »), chacune des deux sociétés étant contrôlées par la société Advanced Biological
Signature d’un traité de fusion Read More »
